Adamis Pharmaceuticals Corp (ADMP)

[ShortsRClowns]

"Struggles for Other COVID-19 Antivirals

Most COVID-19 antivirals have been shown to have weak efficacy in hospitalized patients, with the most promising antivirals only showing significant benefit in patients who have some symptoms but aren’t at risk of having to go to the hospital. It is widely known that remdesivir has a modest effect in a specific set of hospitalized patients, and with many other antivirals blocking the same target (RdRp- RNA-dependent RNA polymerase) as remdesivir, it is no surprise that the likes of Atea Pharmaceuticals Inc. AVIR +0.44%
and Roche Holdings AG’s (OTCMKTS: RHHBY) AT-527 showed disappointing results even in the outpatient setting. Other antivirals targeting RdRp like Appili Therapeutics Inc.’s (OTCMKTS: APLIF) favipiravir and Adamis Pharmaceuticals Corp.’s ADMP -1.85%
TEMPOL might run into the same efficacy issues.

TEMPOL, despite targeting RdRp that has shown to be a weak target for SARS-CoV-2 (COVID-19), has a better chance than some of the other RdRp-targeting antivirals since it also has anti-inflammatory properties, setting it apart as a dual-mechanism of action (MOA) antiviral. That designation is important since COVID-19 patients can exhibit increased inflammation, so blocking the virus from replicating while also decreasing inflammation might have an increased effect on treating patients. However, according to the publication discussed below, Tollovir, TOMDF’s antiviral, is the only antiviral with a triple MOA and is poised to be the best-performing COVID-19 antiviral in the playing field."

Further down in article discusses what it believes could be a better drug from Todos Medical...Tollovir.

https://www.benzinga.com/general/biotech/21/10/23707034/is-pfizer-conceding-race-in-hospitalized-covid-because-of-todos-medicals-triple-moa-antiviral